Rotigotine Schwarz Pharma.
Schwarz Pharma AG, under license from Aderis Pharmaceuticals Inc, is developing rotigotine CDS, a once-daily transdermal patch formulation of rotigotine, which is a naphthol-derived selective D(2) dopamine agonist, for the potential treatment of Parkinson's disease and restless legs syndrome.